HC Wainwright Has Lowered Expectations for WAVE Life Sciences (NASDAQ:WVE) Stock Price

Posted by George Bondi on May 19th, 2026

WAVE Life Sciences (NASDAQ:WVE – Get Free Report) had its price objective lowered by stock analysts at HC Wainwright from $18.00 to $13.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 103.13% from the company’s previous close.

A number of other brokerages have also recently issued reports on WVE. Mizuho increased their price objective on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. Wells Fargo & Company lowered their target price on shares of WAVE Life Sciences from $27.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, March 27th. Citigroup dropped their target price on shares of WAVE Life Sciences from $30.00 to $24.00 and set a “buy” rating for the company in a report on Monday, May 4th. Wedbush raised their price target on WAVE Life Sciences from $33.00 to $35.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Finally, Cantor Fitzgerald boosted their price objective on WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Fourteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $27.19.

View Our Latest Report on WVE

WAVE Life Sciences Trading Down 5.5%

Shares of NASDAQ:WVE opened at $6.40 on Tuesday. The stock has a 50 day moving average of $8.65 and a 200 day moving average of $11.22. The company has a market cap of $1.23 billion, a PE ratio of -6.04 and a beta of -1.32. WAVE Life Sciences has a 12-month low of $5.02 and a 12-month high of $21.73.

WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.21. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%. The company had revenue of $38.25 million during the quarter, compared to analyst estimates of $8.45 million. Equities research analysts predict that WAVE Life Sciences will post -1.16 earnings per share for the current fiscal year.

Insider Activity at WAVE Life Sciences

In other news, insider Chris Francis sold 33,194 shares of the business’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $15.05, for a total value of $499,569.70. Following the transaction, the insider owned 61,867 shares of the company’s stock, valued at approximately $931,098.35. The trade was a 34.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 24.30% of the company’s stock.

Institutional Trading of WAVE Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GSK plc bought a new position in shares of WAVE Life Sciences during the 4th quarter valued at about $310,177,000. Darwin Global Management Ltd. bought a new stake in shares of WAVE Life Sciences in the fourth quarter worth about $125,168,000. Federated Hermes Inc. lifted its position in shares of WAVE Life Sciences by 678,144.7% in the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock worth $27,455,000 after buying an additional 3,750,140 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of WAVE Life Sciences by 83.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock worth $125,927,000 after buying an additional 3,362,880 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after buying an additional 2,500,000 shares during the last quarter. 89.73% of the stock is currently owned by institutional investors.

WAVE Life Sciences Company Profile

(Get Free Report)

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.